Diabetic foot ulcers are a "Sword of Damocles" hanging over the heads of many diabetic patients. The reason these wounds fail to heal for months or even years is far more complex than simple "malnutrition." A recent study, jointly conducted by several top research institutions in my country, has revealed the underlying mechanisms and proposed an innovative cell-free therapy: utilizing extracellular vesicles—"intelligent couriers"—released from specially cultured three-dimensional stem cells to reverse the aging of vascular endothelial cells and fundamentally restart the tissue repair process.

This research was jointly completed by a research team from the Second Hospital of Lanzhou University, Xijing Hospital of the Fourth Military Medical University, the Affiliated Hospital of Jiangnan University, and the Gansu Provincial Key Laboratory of Stem Cell and Gene Drugs. It was published in the authoritative journal Burns & Trauma on June 22, 2026.

For a long time, the medical community has known that angiogenesis is difficult in diabetic wounds, but the cause has generally been attributed to a lack of growth factors in a high-glucose environment. This study, however, used advanced single-cell RNA sequencing technology to create the first precise map of vascular endothelial cells in diabetic foot ulcer tissue, leading to a crucial discovery: these microvascular cells are not simply idling, but have prematurely aged. They have lost their normal function, and most importantly, the translation factories within their cells responsible for synthesizing all the proteins needed for repair have almost completely ceased functioning.

Based on this discovery, the research team turned their attention to extracellular vesicles derived from adipose-derived mesenchymal stem cells—natural nanoparticles rich in bioactive substances. However, they astutely realized that stem cells traditionally grown "flat" in two-dimensional culture dishes gradually lose their vitality and secretory function, and the released vesicles are not "effective". 

To this end, researchers constructed a three-dimensional culture system that more closely resembles the in vivo environment, allowing stem cells to aggregate into spherical growth. Extracellular vesicles extracted from these "vibrant" three-dimensional stem cells were named tdASC-EVs, and they seemed to have been given more powerful instructions.

tdASC-EVs exhibited a significant "rejuvenating" effect on human dermal microvascular endothelial cells that aged due to high glucose levels. Experiments showed that it could effectively reduce cellular aging markers, decrease oxidative damage, repair damaged mitochondrial function, and promote the reformation of tubular structures in cells.

The core mechanism lies in the fact that tdASC-EVs precisely reset the cell's internal "protein translation production line." The key player in this production line is a signaling pathway called **PI3K/AKT/mTOR/4EBP1**. Under high glucose conditions, signal transduction in this pathway is inhibited, leading to impaired protein translation initiation. The arrival of tdASC-EVs reactivates this pathway, causing phosphorylation of the crucial molecule 4EBP1 and releasing the previously "held" translation initiation factor eIF4E. As a result, the cell regains its ability to synthesize proteins necessary for large-scale angiogenesis and repair. When researchers blocked this pathway with inhibitors, the vesicle's therapeutic effect disappeared; however, using a phosphorylated active protein construct, the repair effect was reproduced, definitively validating this crucial mechanism.

The efficacy of this therapy has been progressively validated in animal models. In diabetic mice, tdASC-EVs not only significantly accelerated wound closure and improved local blood perfusion, but also promoted the formation of more healthy microvessels and remodeled the structure of collagen, making it more orderly arranged and reducing scarring.

Even more convincingly, the research team tested the technology on a diabetic Bama miniature pig model that more closely resembles that of humans. The results showed that tdASC-EVs were significantly more effective than traditionally cultured two-dimensional stem cell vesicles. Wounds treated with tdASC-EVs not only healed faster but also exhibited denser angiogenesis, smaller scarring, and more complete tissue regeneration. This success in a large animal model instills strong confidence in future clinical translation. 

The authors of the study concluded, "The problem with diabetic wounds is not only the lack of new blood vessels, but also the premature aging of the cells that should be building these vessels. By improving the way stem cells are cultured, we obtained more robust extracellular vesicles that can reactivate the cell's own repair mechanisms."

This work presents a promising cell-free therapeutic strategy. Compared to direct stem cell transplantation, extracellular vesicle therapy eliminates the need for live cells, offering natural advantages in storage, standardized production, and reduced risk of immune rejection. However, this therapy remains in the preclinical stage. The research team points out that future studies will need to identify which proteins within the vesicles are key to its efficacy, validate its pathways in more refined gene models, and systematically evaluate its long-term biodistribution, safety, and optimal treatment regimen. This research undoubtedly illuminates a path to new life for countless patients suffering from diabetic foot ulcers.